A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention.

Trial Profile

A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Tirofiban (Primary) ; Eptifibatide
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms SAVI-PCI
  • Most Recent Events

    • 15 Feb 2015 Planned End Date changed from 1 Sep 2014 to 1 Mar 2016 as reported by ClinicalTrials.gov.
    • 15 Feb 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Mar 2016 as reported by ClinicalTrials.gov.
    • 05 Nov 2013 Planned number of patients changed from 600 to 675 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top